Royalty Pharma plc
Close on Nov 20, 2026Market cap $39.36BP/E 38.9Yield –
Royalty Pharma Investment-Grade Senior Notes Weighted-Average Duration by Quarter
Investment-Grade Senior Notes Weighted-Average Duration (years)
Royalty Pharma Investment-Grade Senior Notes Weighted-Average Duration: 12.0 years in Q3 2026.
Where the Q3 2026 figure comes from
“$8.8bn with weighted average duration of ~12 years; total leverage of 2.7x(1), net leverage of 2.5x(2)”
Source: Royalty Pharma Quarterly Earnings Presentation (Q3 2026) ↗
Reported in Royalty Pharma Quarterly Earnings Presentations (Q4 2025 - Q3 2026).
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Investment-Grade Senior Notes Weighted-Average Duration (years) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 12.0 | – | Royalty Pharma Quarterly Earnings Presentation (Q3 2026) ↗ |
| Q2 2026 | Jun 30, 2026 | 12.0 | – | Royalty Pharma Quarterly Earnings Presentation (Q2 2026) ↗ |
| Q1 2026 | Mar 31, 2026 | 12.0 | – | Royalty Pharma Quarterly Earnings Presentation (Q1 2026) ↗ |
| Q4 2025 | Dec 31, 2025 | 13.0 | – | Royalty Pharma Quarterly Earnings Presentation (Q4 2025) ↗ |
Cite this data
StockData. (2026). Royalty Pharma Investment-Grade Senior Notes Weighted-Average Duration (years), quarterly Q4 2025–Q3 2026 [Data set]. Compiled from Royalty Pharma SEC filings and investor materials. https://stockdatahq.com/stocks/rprx/kpis/debt-weighted-average-duration
See every metric in the Royalty Pharma KPI table. Data updated Nov 14, 2026.
See a number that looks wrong?